The main feature of tumor cells is their ability to divide unrestrictedly. Cellular division critically depends on successful mitosis. Thus, perhaps unsurprisingly, among the most powerful anticancer drugs are the ones that target mitosis. Proper segregation of chromosomes during mitosis is ensured by a highly coordinated and dynamic process of polymerization/depolymerization of mitotic spindle microtubules. Hence, natural microtubule-poisoning drugs, such as Paclitaxel (PTX or Taxol) and vinblastine are commonly used as anti-neoplastic agents for the treatment of solid tumors, including breast, ovarian, lung, and head and neck malignancies.[@R1] The consequence of treatment with these drugs is mitotic arrest, which, in turn, activates the spindle assembly checkpoint (SAC). Tumor cells employ several mechanisms to skip SAC, including ubiquitin-dependent degradation/inactivation of the cyclin B/Cdk1 complex by the anaphase-promoting complex/cyclosome (APC/C). The latter is an E3 ubiquitin ligase that operates via 26S proteasome[@R2] and is positively regulated by cyclin B/Cdk1-mediated phosphorylation. Inactivation of Cdk1 results in attenuation of the APC/C activity, which, in turn, is required for degradation of securin and the release of sister chromatids, thus promoting the metaphase-to-anaphase transition. Another mechanism of slippage from SAC is attenuation of mitotic kinase Aurora A, which is necessary for the proper separation of centrosomes after the mitotic spindle has been formed.[@R3] However, for escaping SAC, cancer cells pay their toll, i.e., they die because of mitotic catastrophe.[@R4]

Unfortunately, during the prolonged anti-mitotic therapy, tumor cells acquire resistance to PTX by overexpressing mutated versions of tubulin proteins inert to PTX, or by modulating the expression of micro-RNAs that target the Bcl-2 family of proteins. Therefore, the problem of overcoming PTX resistance urgently requires its solution and warrants extensive studies in this area. The idea of combining physiological (39.5--45 °C) hyperthermia (HT) with cancer therapy is currently being actively explored in clinical studies. For example, several phase III trials comparing radiotherapy alone or with hyperthermia have shown a beneficial effect of hyperthermia in terms of local control of recurrent breast cancer and malignant melanoma and survival (e.g., head and neck lymph-node metastases, glioblastoma, cervical carcinoma, etc.).[@R5]

In this respect, the study by Giovinazzi et al. published in the present issue of *Cell Cycle* is timely and interesting. The authors showed that hyperthermia (HT) and APC/C inhibition have opposite effects on the fate of tumor cells arrested in mitosis; HT provoked mitotic slippage of breast tumor cells, resulting in mitotic catastrophe, whereas the inhibitor of APC/C, proTAME, on the contrary, prolonged the time of mitosis and led to apoptosis. Importantly, these effects were independent of the means by which cells were arrested in mitosis, i.e., either by treatment with Aurora A inhibitor MLN8054 or with Paclitaxel (PTX). On the therapeutic side, the authors showed that HT enhanced the cytotoxic effect of PTX on breast cancer cells irrespective of their status toward sensitivity to PTX.

How HT promotes the escape of PTX-arrested cells is yet not clear. In general, HT was reported to disrupt the microtubule network. However, in the case of prior PTX treatment, the microtubule bundles remained intact.[@R6] The most apparent effect of HT was observed at the level of centrosomes. In this respect, members of the heat shock proteins family (HSPs) play the pivotal role in assisting repair of centrosomes after heat shock. Microinjection of Hsp73 antibodies retarded recovery of the interphase centrosome structure and microtubule re-assembly after HT, whereas injection of purified Hsp73 before heat shock enhanced these processes.[@R7] Collectively, these findings suggest an intriguing possibility that the combination of chemical inhibitors of HSPs (17-AAG and KNK437, or quercetin)[@R8] with PTX and HT will facilitate the slippage of cancer cells from mitosis and, hence, augment the antitumor effect of combination therapy, especially in the case of PTX-resistant malignancies.
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